iRhythm Holdings Reports Q2 Results; $50M Patent Settlement, Vital Connect Deal

What Happened

• iRhythm Holdings (through subsidiary iRhythm Technologies) filed an 8‑K on August 6, 2026. The filing discloses three material items: a patent settlement with Baxter, a press release with the Company’s financial results for the quarter ended June 30, 2026, and a press release announcing a definitive agreement to acquire Vital Connect, Inc.
• On July 31, 2026, iRhythm Technologies and Baxter entered into a Settlement and License Agreement to resolve outstanding patent litigation. iRhythm will pay Baxter $50.0 million and both parties granted each other a worldwide, royalty‑free, non‑exclusive, fully paid‑up license covering the patents asserted in the litigation (and related patents) for products and services involving certain cardiac-monitoring sensors.

Key Details

• Settlement payment: $50,000,000 by iRhythm Technologies to Baxter (Settlement dated July 31, 2026).
• License terms: worldwide, royalty‑free, non‑exclusive, fully paid‑up license for patents related to certain cardiac‑monitoring sensors; no ongoing royalties or other compensation except the $50M payment.
• Covenants: each party agreed to a six‑year covenant not to sue regarding exploitation of the licensed products/services and agreed not to challenge the licensed patents unless those patents are enforced against them or their affiliates.
• Corporate disclosures: press release with Q2 2026 financial results furnished as Exhibit 99.1 and press release announcing the proposed acquisition of Vital Connect furnished as Exhibit 99.2 (both dated August 6, 2026).

Why It Matters

• Legal risk & clarity: settling the patent disputes removes ongoing litigation uncertainty with Baxter and establishes cross‑licenses that clarify freedom to operate for certain sensor-related products.
• Financial impact: the settlement requires a $50M cash payment that will affect the company’s cash/liquidity and will be reflected in forthcoming public filings (the settlement agreement will be filed as an exhibit to the Company’s 10‑Q).
• Strategic development: iRhythm announced a definitive agreement to acquire Vital Connect (details in the August 6 press release), a move the company has publicly disclosed alongside its quarterly results. Investors should review the Company’s Q2 press release and subsequent filings for quantitative financial details and any disclosed terms of the Vital Connect transaction.